68Ga-DOTA-DiPSMA PET/CT Imaging: Biodistribution, Dosimetry, and Preliminary Application in Prostate Cancer
Open Access
- 28 January 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 9, 811972
- https://doi.org/10.3389/fbioe.2021.811972
Abstract
Purpose This prospective trial aimed to evaluate the safety, dosimetry, biodistribution, of a novel theranostic probe 68Ga-DOTA-DiPSMA. Also, we have performed the first preliminary application with 68Ga-DOTA-DiPSMA in prostate cancer (PCa) patients. Methods Five healthy volunteers and ten PCa patients were injected with an intravenous bolus of 68Ga-DOTA-DiPSMA. They received serial whole-body PET scans from the time of injection up to 60 min post-injection, with a second PET/CT scanning at 120 min post-injection. In PCa patients, low-dose CT scan, whole-body PET was performed with 2 min per bed position in 40 min post-injection. Absorbed organ doses and effective doses were calculated using OLINDA/EXM. Normal organ uptake and tumor lesion uptake were measured. A lesion-by-lesion analysis was performed. Results 68Ga-DOTA-DiPSMA administration was safe and well-tolerated. The kidneys received the highest absorbed dose (114.46 ± 29.28 uSv/MBq), followed by the urinary bladder wall (100.82 ± 46.22 uSv/MBq) in accordance with the expected Prostate-Specific Membrane Antigen (PSMA) renal excretion of the tracer. The mean effective dose was 19.46 ± 1.73 μSv/MBq. The SUVmax of 68Ga-DOTA-DiPSMA PET/CT for PCa lesions, bone metastases, and lymph node metastases were 4.41 ± 2.72, 2.95 ± 1.11 and 3.26 ± 1.20, respectively. Conclusion Injection of 68Ga-DOTA-DiPSMA is safe and associated with low absorbed and effective doses. 68Ga-DOTA-DiPSMA shows favorable kinetics and imaging characteristics in patients that warrant further head-to-head comparison to validate 68Ga-DOTA-DiPSMA as an alternative for gallium-68-labelled PSMA clinical PET. Low non-specific uptake in normal organs of 68Ga-DOTA-DiPSMA indicates potential radioligand therapy (RLT) application when labeled with 177Lu, 90Y, or 225Ac.Funding Information
- Natural Science Foundation of Fujian Province
- National Natural Science Foundation of China
- Fujian Provincial Health Technology Project
This publication has 25 references indexed in Scilit:
- Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Biodistribution and radiation dosimetry of 68Ga-PSMA HBED CC—a PSMA specific probe for PET imaging of prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617Journal of Nuclear Medicine, 2016
- MRI versus 68Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- Prostate cancerThe Lancet, 2015
- The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Assessment of Prostate Cancer Aggressiveness Using Dynamic Contrast-enhanced Magnetic Resonance Imaging at 3 TEuropean Urology, 2013
- Platelet-rich plasma as a scaffold for injectable soft-tissue augmentationCytotherapy, 2010
- Prostate specific membrane antigen- a target for imaging and therapy with radionuclides.2010